|
1
|
Braeckmans K, De Smedt SC, Leblans M,
Pauwels R and Demeester J: Encoding microcarriers: Present and
future technologies. Nat Rev Drug Discov. 1:447–456. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ginsburg GS and Willard HF: Genomic and
personalized medicine: Foundations and applications. Transl Res.
154:277–287. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hertz DL and McLeod HL: Use of
pharmacogenetics for predicting cancer prognosis and treatment
exposure, response and toxicity. J Hum Genet. 58:346–352. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kaddurah-Daouk R and Weinshilboum RM;
Pharmacometabolomics Research Network: Pharmacometabolomics:
Implications for clinical pharmacology and systems pharmacology.
Clin Pharmacol Ther. 95:154–167. 2014. View Article : Google Scholar
|
|
5
|
Roses AD, Saunders AM, Lutz MW, Zhang N,
Hariri AR, Asin KE, Crenshaw DG, Budur K, Burns DK and Brannan SK:
New applications of disease genetics and pharmacogenetics to drug
development. Curr Opin Pharmacol. 14:81–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vizirianakis IS: Challenges in current
drug delivery from the potential application of pharmacogenomics
and personalized medicine in clinical practice. Curr Drug Deliv.
1:73–80. 2004. View Article : Google Scholar
|
|
7
|
Vizirianakis IS: Improving pharmacotherapy
outcomes by pharmacogenomics: From expectation to reality?
Pharmacogenomics. 6:701–711. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vizirianakis IS: Clinical translation of
genotyping and haplotyping data: Implementation of in vivo
pharmacology experience leading drug prescription to
pharmacotyping. Clin Pharmacokinet. 46:807–824. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vizirianakis IS: Advancement of
pharmacogenomics toward pharmacotyping in drug prescription:
Concepts, challenges, and perspectives for personalized medicine.
Handbook of Personalized Medicine: Advances in Nanotechnology, Drug
Delivery and Therapy. Vizirianakis IS: Pan Stanford Publishing;
Singapore: pp. 893–952. 2014, View Article : Google Scholar
|
|
10
|
Pirmohamed M: Personalized
pharmacogenomics: Predicting efficacy and adverse drug reactions.
Annu Rev Genomics Hum Genet. 15:349–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ahn K, Luo J, Berg A, Keefe D and Wu R:
Functional mapping of drug response with
pharmacodynamic-pharmacokinetic principles. Trends Pharmacol Sci.
31:306–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Daka A and Peer D: RNAi-based
nanomedicines for targeted personalized therapy. Adv Drug Deliv
Rev. 64:1508–1521. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Debbage P: Targeted drugs and
nanomedicine: Present and future. Curr Pharm Des. 15:153–172. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Huttenhower C and Hofmann O: A quick guide
to large-scale genomic data mining. PLOS Comput Biol.
6:e10007792010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Janowski M, Bulte JW and Walczak P:
Personalized nano-medicine advancements for stem cell tracking. Adv
Drug Deliv Rev. 64:1488–1507. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mura S and Couvreur P: Nanotheranostics
for personalized medicine. Adv Drug Deliv Rev. 64:1394–1416. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Petersen AL, Hansen AE, Gabizon A and
Andresen TL: Liposome imaging agents in personalized medicine. Adv
Drug Deliv Rev. 64:1417–1435. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ryu JH, Koo H, Sun IC, Yuk SH, Choi K, Kim
K and Kwon IC: Tumor-targeting multi-functional nanoparticles for
theragnosis: New paradigm for cancer therapy. Adv Drug Deliv Rev.
64:1447–1458. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vizirianakis IS, Chatzopoulou M,
Bonovolias ID, Nicolaou I, Demopoulos VJ and Tsiftsoglou AS: Toward
the development of innovative bifunctional agents to induce
differentiation and to promote apoptosis in leukemia: Clinical
candidates and perspectives. J Med Chem. 53:6779–6810. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wieland M and Fussenegger M: Reprogrammed
cell delivery for personalized medicine. Adv Drug Deliv Rev.
64:1477–1487. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cook D, Brown D, Alexander R, March R,
Morgan P, Satterthwaite G and Pangalos MN: Lessons learned from the
fate of Astrazeneca's drug pipeline: A five-dimensional framework.
Nat Rev Drug Discov. 13:419–431. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cree IA: Designing personalised cancer
treatments. J Control Release. 172:405–409. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hillgren KM, Keppler D, Zur AA, Giacomini
KM, Stieger B, Cass CE and Zhang L; International Transporter
Consortium: Emerging transporters of clinical importance: An update
from the International Transporter Consortium. Clin Pharmacol Ther.
94:52–63. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang M, Shen A, Ding J and Geng M:
Molecularly targeted cancer therapy: Some lessons from the past
decade. Trends Pharmacol Sci. 35:41–50. 2014. View Article : Google Scholar
|
|
25
|
Ingelman-Sundberg M: Pharmacogenetics of
cytochrome P450 and its applications in drug therapy: The past,
present and future. Trends Pharmacol Sci. 25:193–200. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jain KK: Innovative diagnostic
technologies and their significance for personalized medicine. Mol
Diagn Ther. 14:141–147. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee JW, Aminkeng F, Bhavsar AP, Shaw K,
Carleton BC, Hayden MR and Ross CJ: The emerging era of
pharmacogenomics: Current successes, future potential, and
challenges. Clin Genet. 86:21–28. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ntziachristos V and Razansky D: Molecular
imaging by means of multispectral optoacoustic tomography (MSOT).
Chem Rev. 110:2783–2794. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ntziachristos V, Schellenberger EA, Ripoll
J, Yessayan D, Graves E, Bogdanov A Jr, Josephson L and Weissleder
R: Visualization of antitumor treatment by means of fluorescence
molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl
Acad Sci USA. 101:12294–12299. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pirmohamed M: Pharmacogenetics: Past,
present and future. Drug Discov Today. 16:852–861. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sadee W: Pharmacogenomic biomarkers:
Validation needed for both the molecular genetic mechanism and
clinical effect. Pharmacogenomics. 12:675–680. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vizirianakis IS: Nanomedicine and
personalized medicine toward the application of pharmacotyping in
clinical practice to improve drug-delivery outcomes. Nanomedicine.
7:11–17. 2011. View Article : Google Scholar
|
|
33
|
Flowers CR and Veenstra D: The role of
cost-effectiveness analysis in the era of pharmacogenomics.
Pharmacoeconomics. 22:481–493. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Payne K and Shabaruddin FH:
Cost-effectiveness analysis in pharmacogenomics. Pharmacogenomics.
11:643–646. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sorich MJ, Wiese MD and Pekarsky B:
Cost-effectiveness of geno-typing to guide treatment.
Pharmacogenomics. 15:727–729. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wong WB, Carlson JJ, Thariani R and
Veenstra DL: Cost effectiveness of pharmacogenomics: A critical and
systematic review. Pharmacoeconomics. 28:1001–1013. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu AHB, Babic N and Yeo KT: Implementation
of pharmacogenomics into the clinical practice of therapeutics:
Issues for the clinician and the laboratorian. Per Med. 6:315–327.
2009. View Article : Google Scholar
|
|
38
|
Fleeman N, McLeod C, Bagust A, Beale S,
Boland A, Dundar Y, Jorgensen A, Payne K, Pirmohamed M, Pushpakom
S, et al: The clinical effectiveness and cost-effectiveness of
testing for cytochrome P450 polymorphisms in patients with
schizophrenia treated with antipsychotics: A systematic review and
economic evaluation. Health Technol Assess. 14:1–157. iii2010.
View Article : Google Scholar
|
|
39
|
Gurwitz D, Rodríguez-Antona C, Payne K,
Newman W, Gisbert JP, de Mesa EG and Ibarreta D: Improving
pharmacovigilance in Europe: TPMT genotyping and phenotyping in the
uk and spain. Eur J Hum Genet. 17:991–998. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Thompson AJ, Newman WG, Elliott RA,
Roberts SA, Tricker K and Payne K: The cost-effectiveness of a
pharmacogenetic test: A trial-based evaluation of TPMT genotyping
for azathioprine. Value Health. 17:22–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
van den Akker-van Marle ME, Gurwitz D,
Detmar SB, Enzing CM, Hopkins MM, Gutierrez de Mesa E and Ibarreta
D: Cost-effectiveness of pharmacogenomics in clinical practice: A
case study of thiopurine methyltransferase genotyping in acute
lymphoblastic leukemia in Europe. Pharmacogenomics. 7:783–792.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Phillips KA, Ann Sakowski J, Trosman J,
Douglas MP, Liang SY and Neumann P: The economic value of
personalized medicine tests. Genet Med. 16:251–257. 2014.
View Article : Google Scholar :
|
|
43
|
Shabaruddin FH and Payne K: Evaluating the
cost-effectiveness of pharmacogenomics in clinical practice.
Handbook of personalized Medicine: Advances in nanotechnology, Drug
Delivery and Therapy. Vizirianakis IS: Pan stanford publishing;
Singapore: pp. 779–812. 2014, View Article : Google Scholar
|
|
44
|
Poulin P, Jones RD, Jones HM, Gibson CR,
Rowland M, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, et al: PHRMA
CPCDC initiative on predictive models of human pharmacokinetics,
part 5: Prediction of plasma concentration-time profiles in human
using the physiologically-based pharmacokinetic modeling approach.
J Pharm Sci. 100:4127–4157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ring BJ, Chien JY, Adkison KK, Jones HM,
Rowland M, Jones RD, Yates JW, Ku MS, Gibson CR, He H, et al: PHRMA
CPCDC initiative on predictive models of human pharmacokinetics,
part 3: Comparative assessment of prediction methods of human
clearance. J Pharm Sci. 100:4090–4110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bates S: Progress towards personalized
medicine. Drug Discov Today. 15:115–120. 2010. View Article : Google Scholar
|
|
47
|
Fu G, Liu J, Luo J, Zhong W, Wang Y, Wang
N and Wu R: Systems mapping: A computational tool for personalized
medicine. Handbook of personalized Medicine: Advances in
nanotechnology, Drug Delivery and Therapy. Vizirianakis IS: Pan
Stanford Publishing; Singapore: pp. 321–340. 2014, View Article : Google Scholar
|
|
48
|
Wu R, Tong C, Wang Z, Mauger D, Tantisira
K, Szefler SJ, Chinchilli VM and Israel E: A conceptual framework
for pharmacodynamic genome-wide association studies in
pharmacogenomics. Drug Discov Today. 16:884–890. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hong H, Perkins R, Shi L, Fang H, Mendrick
DL and Tong W: Molecular biomarkers for personalized medicine.
Handbook of personalized Medicine: Advances in nanotechnology, Drug
Delivery and Therspy. Vizirianakis IS: Pan stanford publishing;
Singapore: pp. 607–644. 2014, View Article : Google Scholar
|
|
50
|
Gonzalez de Castro D, Clarke PA,
Al-Lazikani B and Workman P: Personalized cancer medicine:
Molecular diagnostics, predictive biomarkers, and drug resistance.
Clin Pharmacol Ther. 93:252–259. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yap TA, Sandhu SK, Workman P and de Bono
JS: Envisioning the future of early anticancer drug development.
Nat Rev Cancer. 10:514–523. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rubin EH and Gilliland DG: Drug
development and clinical trials - the path to an approved cancer
drug. Nat Rev Clin Oncol. 9:215–222. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Vizirianakis IS and Fatouros DG:
Personalized nanomedicine: Paving the way to the practical clinical
utility of genomics and nanotechnology advancements. Adv Drug Deliv
Rev. 64:1359–1362. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Vizirianakis IS: Handbook of personalized
Medicine: Advances in Nanotechnology, Drug Delivery, and Therapy.
Pan Stanford Publishing; Singapore: 2014, View Article : Google Scholar
|
|
55
|
Swanson TW, Akkari PA, Arbuckle JB,
Grossman I, Sundseth SS and Roses AD: Methodology to enable
integration of genomic knowledge into drug development. Handbook of
Personalized Medicine: Advances in nanotechnology, Drug Delivery
and Therpy. Vizirianakis IS: Pan stanford publishing; Singapore:
pp. 645–684. 2014, View Article : Google Scholar
|
|
56
|
Jamei M, Rowland YK and Rostami-Hodjegan
A: Framework, organization, and applications of the Simcyp
population-based simulator to support new drug development.
Handbook of personalized Medicine: Advances in nanotechnology, Drug
Delivery and Therapy. Vizirianakis IS: Pan stanford publishing;
Singapore: pp. 685–726. Pan stanford publishing; Singapore: 2014,
View Article : Google Scholar
|
|
57
|
Amstutz U and Carleton BC: Pharmacogenetic
testing: Time for clinical practice guidelines. Clin Pharmacol
Ther. 89:924–927. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Johnson JA, Gong L, Whirl-Carrillo M, Gage
BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MT, Pirmohamed
M, et al Clinical pharmacogenetics Implementation Consortium:
Clinical Pharmacogenetics Implementation Consortium Guidelines for
CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol
Ther. 90:625–629. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Relling MV, Gardner EE, Sandborn WJ,
Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE and
Klein TE; Clinical Pharmacogenetics Implementation Consortium:
Clinical Pharmacogenetics Implementation Consortium guidelines for
thiopurine methyltransferase genotype and thiopurine dosing. Clin
Pharmacol Ther. 89:387–391. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Relling MV and klein TE: CPIC: Clinical
pharmacogenetics Implementation Consortium of the Pharmacogenomics
Research network. Clin Pharmacol Ther. 89:464–467. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Scott SA, Sangkuhl K, Gardner EE, Stein
CM, Hulot JS, Johnson JA, Roden DM, Klein TE and Shuldiner AR;
Clinical Pharmacogenetics Implementation Consortium: Clinical
Pharmacogenetics Implementation Consortium guidelines for
cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
Clin Pharmacol Ther. 90:328–332. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Swen JJ, Nijenhuis M, de Boer A, Grandia
L, Maitland-van der zee AH, Mulder H, Rongen GA, van Schaik RH,
Schalekamp T, Touw DJ, et al: Pharmacogenetics: From bench to byte
- an update of guidelines. Clin Pharmacol Ther. 89:662–673. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Workman P: The opportunities and
challenges of personalized genome-based molecular therapies for
cancer: Targets, technologies, and molecular chaperones. Cancer
Chemother. 52(Suppl 1): S45–S56. 2003. View Article : Google Scholar
|
|
65
|
Jain RK: Normalizing tumor
microenvironment to treat cancer: Bench to bedside to biomarkers. J
Clin Oncol. 31:2205–2218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Khawar IA, Kim JH and Kuh HJ: Improving
drug delivery to solid tumors. J Control Release. 201:78–89. 2015.
View Article : Google Scholar
|
|
67
|
Scott JG, Hjelmeland AB, Chinnaiyan P,
Anderson AR and Basanta D: Microenvironmental variables must
influence intrinsic phenotypic parameters of cancer stem cells to
affect tumourigenicity. PLOS Comput Biol. 10:e10034332014.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Watnick RS: The role of the tumor
microenvironment in regulating angiogenesis. Cold Spring Harb
Perspect Med. 2:a0066762012. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kirtane AR, Siegel RA and Panyam J: A
pharmacokinetic model for quantifying the effect of vascular
permeability on the choice of drug carrier: A framework for
personalized nanomedicine. J Pharm Sci. 104:1174–1186. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Moss DM and siccardi M: Optimizing
nanomedicine phar-macokinetics using physiologically based
pharmacokinetics modelling. Br J Pharmacol. 171:3963–3979. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Andre F, Mardis E, Salm M, Soria JC, Siu
LL and Swanton C: Prioritizing targets for precision cancer
medicine. Ann Oncol. 25:2295–2303. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Collins FS and Varmus H: A new initiative
on precision medicine. N Engl J Med. 372:793–795. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Doudican NA, Kumar A, Singh NK, Nair PR,
Lala DA, Basu K, Talawdekar AA, Sultana Z, Tiwari KK, Tyagi A, et
al: Personalization of cancer treatment using predictive
simulation. J Transl Med. 13:432015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Roychowdhury S and Chinnaiyan AM:
Translating genomics for precision cancer medicine. Annu Rev
Genomics Hum Genet. 15:395–415. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Binkhorst L, Mathijssen RH, Jager A and
van Gelder T: Individualization of tamoxifen therapy: Much more
than just CYP2D6 genotyping. Cancer Treat Rev. 41:289–299. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Smith GL: The long and short of tamoxifen
therapy: A review of the ATLAs trial. J Adv Pract Oncol. 5:57–60.
2014.PubMed/NCBI
|
|
77
|
Borges S, Desta Z, Li L, Skaar TC, Ward
BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, et al:
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen
metabolism: Implication for optimization of breast cancer
treatment. Clin Pharmacol Ther. 80:61–74. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Flockhart D: CYP2D6 genotyping and the
pharmacogenetics of tamoxifen. Clin Adv Hematol Oncol. 6:493–494.
2008.PubMed/NCBI
|
|
79
|
Jin Y, Desta Z, Stearns V, Ward B, Ho H,
Lee KH, Skaar T, Storniolo AM, Li L, Araba A, et al: CYP2D6
genotype, antidepressant use, and tamoxifen metabolism during
adjuvant breast cancer treatment. J Natl Cancer Inst. 97:30–39.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Stearns V, Johnson MD, Rae JM, Morocho A,
Novielli A, Bhargava P, Hayes DF, Desta Z and Flockhart DA: Active
tamoxifen metabolite plasma concentrations after coadministration
of tamoxifen and the selective serotonin reuptake inhibitor
paroxetine. J Natl Cancer Inst. 95:1758–1764. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Dickschen K, Willmann S, Thelen K, Lippert
J, Hempel G and Eissing T: Physiologically based pharmacokinetic
modeling of tamoxifen and its metabolites in women of different
CYP2D6 phenotypes provides new insight into the tamoxifen mass
balance. Front Pharmacol. 3:922012. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Drbohlavova J, Chomoucka J, Adam V,
Ryvolova M, Eckschlager T, Hubalek J and Kizek R: Nanocarriers for
anti-cancer drugs - new trends in nanomedicine. Curr Drug Metab.
14:547–564. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Ballesta A, Zhou Q, Zhang X, Lv H and
Gallo JM: Multiscale design of cell-type-specific
pharmacokinetic/pharmacodynamic models for personalized medicine:
Application to temozolomide in brain tumors. CPT Pharmacometrics
Syst Pharmacol. 3:e1122014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Block M: Physiologically based
pharmacokinetic and pharmacodynamic modeling in cancer drug
development: Status, potential and gaps. Expert Opin Drug Metab
Toxicol. 11:743–756. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Upreti M, Jyoti A and Sethi P: Tumor
microenvironment and nanotherapeutics. Transl Cancer Res.
2:309–319. 2013.
|
|
86
|
Maji R, Dey NS, Satapathy BS, Mukherjee B
and Mondal S: Preparation and characterization of Tamoxifen citrate
loaded nanoparticles for breast cancer therapy. Int J Nanomedicine.
9:3107–3118. 2014.PubMed/NCBI
|
|
87
|
Pandey SK, Ghosh S, Maiti P and Haldar C:
Therapeutic efficacy and toxicity of tamoxifen loaded PLA
nanoparticles for breast cancer. Int J Biol Macromol. 72:309–319.
2015. View Article : Google Scholar
|
|
88
|
Hersh EM, O'Day SJ, Ribas A, Samlowski WE,
Gordon MS, Shechter DE, Clawson AA and Gonzalez R: A phase 2
clinical trial of nab-paclitaxel in previously treated and
chemotherapy-naive patients with metastatic melanoma. Cancer.
116:155–163. 2010.
|
|
89
|
Jehn CF, Boulikas T, Kourvetaris A, Kofla
G, Possinger K and Lüftner D: First safety and response results of
a randomized phase III study with liposomal platin in the treatment
of advanced squamous cell carcinoma of the head and neck (SCCHN).
Anticancer Res. 28:3961–3964. 2008.
|
|
90
|
Mamot C, Ritschard R, Wicki A, Stehle G,
Dieterle T, Bubendorf L, Hilker C, Deuster S, Herrmann R and
Rochlitz C: Tolerability, safety, pharmacokinetics, and efficacy of
doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid
tumours: A phase 1 dose-escalation study. Lancet oncol.
13:1234–1241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Zhao P and Astruc D: Docetaxel
nanotechnology in anticancer therapy. ChemMedChem. 7:952–972. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Baish JW, Stylianopoulos T, Lanning RM,
Kamoun WS, Fukumura D, Munn LL and Jain RK: Scaling rules for
diffusive drug delivery in tumor and normal tissues. Proc Natl Acad
Sci USA. 108:1799–1803. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Bachler G, von Goetz N and Hungerbühler K:
A physiologically based pharmacokinetic model for ionic silver and
silver nanoparticles. Int J Nanomedicine. 8:3365–3382.
2013.PubMed/NCBI
|
|
94
|
Bachler G, von Goetz N and Hungerbuhler K:
Using physiologically based pharmacokinetic (PBPK) modeling for
dietary risk assessment of titanium dioxide (TiO2)
nanoparticles. Nanotoxicology. 9:373–380. 2015. View Article : Google Scholar
|
|
95
|
Liu J, Zheng X, Yan L, Zhou L, Tian G, Yin
W, Wang L, Liu Y, Hu Z, Gu Z, et al: Bismuth sulfide nanorods as a
precision nano-medicine for in vivo multimodal imaging-guided
photothermal therapy of tumor. ACS Nano. 9:696–707. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Mouffouk F, Simão T, Dornelles DF, Lopes
AD, Sau P, Martins J, Abu-salah KM, Alrokayan SA, Rosa da Costa AM
and dos Santos NR: Self-assembled polymeric nanoparticles as new,
smart contrast agents for cancer early detection using magnetic
resonance imaging. Int J Nanomedicine. 10:63–76. 2015.PubMed/NCBI
|
|
97
|
Perera RH, Hernandez C, Zhou H, Kota P,
Burke A and Exner AA: Ultrasound imaging beyond the vasculature
with new generation contrast agents. Wiley Interdiscip Rev Nanomed
Nanobiotechnol. 7:593–608. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Torchilin VP: Multifunctional,
stimuli-sensitive nanoparticulate systems for drug delivery. Nat
Rev Drug Discov. 13:813–827. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Barrett JS, Della Casa Alberighi O, Läer S
and Meibohm B: Physiologically based pharmacokinetic (PBPK)
modeling in children. Clin Pharmacol Ther. 92:40–49. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Chetty M, Li L, Rose R, Machavaram K,
Jamei M, Rostami-Hodjegan A and Gardner I: Prediction of the
pharmacokinetics, pharmacodynamics, and efficacy of a monoclonal
antibody, using a physiologically based pharmacokinetic FcRn model.
Front Immunol. 5:6702014.
|
|
101
|
Diao L and Meibohm B: Pharmacokinetics and
pharmacokinetic-pharmacodynamic correlations of therapeutic
peptides. Clin Pharmacokinet. 52:855–868. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Dostalek M, Gardner I, Gurbaxani BM, Rose
RH and Chetty M: Pharmacokinetics, pharmacodynamics and
physiologically-based pharmacokinetic modelling of monoclonal
antibodies. Clin Pharmacokinet. 52:83–124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Jones HM, Chen Y, Gibson C, Heimbach T,
Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M and Hall SD:
Physiologically based pharmacokinetic modeling in drug discovery
and development: A pharmaceutical industry perspective. Clin
pharmacol Ther. 97:247–262. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
104
|
Dranitsaris G, Amir E and Dorward K:
Biosimilars of biological drug therapies: Regulatory, clinical and
commercial considerations. Drugs. 71:1527–1536. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Wang J, Iyer S, Fielder PJ, Davis JD and
Deng R: Projecting human pharmacokinetics of monoclonal antibodies
from nonclinical data: Comparative evaluation of prediction
approaches in early drug development. Biopharm Drug Dispos. Apr
13–2015.Epub ahead of print. View Article : Google Scholar
|
|
106
|
Bouzom F, Ball K, Perdaems N and Walther
B: Physiologically based pharmacokinetic (PBPK) modelling tools:
How to fit with our needs? Biopharm Drug Dispos. 33:55–71. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Nyberg J, Bazzoli C, Ogungbenro K, Aliev
A, Leonov S, Duffull S, Hooker AC and Mentré F: Methods and
software tools for design evaluation in population
pharmacokinetics-pharmacodynamics studies. Br J Clin Pharmacol.
79:6–17. 2015. View Article : Google Scholar :
|
|
108
|
Rowland M, Peck C and Tucker G:
Physiologically-based pharmacokinetics in drug development and
regulatory science. Annu Rev Pharmacol Toxicol. 51:45–73. 2011.
View Article : Google Scholar
|
|
109
|
Moghimi SM, Hunter AC and Andresen TL:
Factors controlling nanoparticle pharmacokinetics: An integrated
analysis and perspective. Annu Rev Pharmacol Toxicol. 52:481–503.
2012. View Article : Google Scholar
|
|
110
|
Zhang XQ, Xu X, Bertrand N, Pridgen E,
Swami A and Farokhzad OC: Interactions of nanomaterials and
biological systems: Implications to personalized nanomedicine. Adv
Drug Deliv Rev. 64:1363–1384. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Davis ME, Zuckerman JE, Choi CH, Seligson
D, Tolcher A, Alabi CA, Yen Y, Heidel JD and Ribas A: Evidence of
RNAi in humans from systemically administered siRNA via targeted
nanoparticles. Nature. 464:1067–1070. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Gao W, Xiao Z, Radovic-Moreno A, Shi J,
Langer R and Farokhzad OC: Progress in siRNA delivery using
multifunctional nanoparticles. Methods Mol Biol. 629:53–67. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Zhou J, Shum KT, Burnett JC and Rossi JJ:
Nanoparticle-based delivery of RNAi therapeutics: Progress and
challenges. Pharmaceuticals. 6:85–107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Abakumov MA, Nukolova NV, Sokolsky-Papkov
M, Shein SA, Sandalova TO, Vishwasrao HM, Grinenko NF, Gubsky IL,
Abakumov AM, Kabanov AV, et al: VEGF-targeted magnetic
nanoparticles for MRI visualization of brain tumor. Nanomedicine.
11:825–833. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Yohan D and Chithrani BD: Applications of
nanoparticles in nanomedicine. J Biomed nanotechnol. 10:2371–2392.
2014. View Article : Google Scholar
|
|
116
|
Pridgen EM, Alexis F and Farokhzad OC:
Polymeric nanoparticle technologies for oral drug delivery. Clin
Gastroenterol Hepatol. 12:1605–1610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Wright J: Deliver on a promise. Sci Am.
311:S12–S13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Zhang L, Gu FX, Chan JM, Wang AZ, Langer
RS and Farokhzad OC: Nanoparticles in medicine: Therapeutic
applications and developments. Clin Pharmacol Ther. 83:761–769.
2008. View Article : Google Scholar
|
|
119
|
Aoyama T, Omori T, Watabe S, Shioya A,
Ueno T, Fukuda N and Matsumoto Y: Pharmacokinetic/pharmacodynamic
modeling and simulation of rosuvastatin using an extension of the
indirect response model by incorporating a circadian rhythm. Biol
Pharm Bull. 33:1082–1087. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Chetty M, Rose RH, Abduljalil K, Patel N,
Lu G, Cain T, Jamei M and Rostami-Hodjegan A: Applications of
linking PBPK and PD models to predict the impact of genotypic
variability, formulation differences, differences in target binding
capacity and target site drug concentrations on drug responses and
variability. Front Pharmacol. 5:2582014. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Rose RH, Neuhoff S, Abduljalil K, Chetty
M, Rostami-Hodjegan A and Jamei M: Application of a physiologically
based pharmacokinetic model to predict OATP1B1-related variability
in pharmacodynamics of rosuvastatin. CPT Pharmacometrics Syst
Pharmacol. 3:e1242014. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Abbad S, Wang C, Waddad AY, LV H and Zhou
J: Preparation, in vitro and in vivo evaluation of polymeric
nanoparticles based on hyaluronic acid-poly(butyl cyanoacrylate)
and D-alphatocopheryl polyethylene glycol 1000 succinate for
tumor-targeted delivery of morin hydrate. Int J Nanomedicine.
10:305–320. 2015.
|
|
123
|
Abouzeid AH, Patel NR, Sarisozen C and
Torchilin VP: Transferrin-targeted polymeric micelles co-loaded
with curcumin and paclitaxel: Efficient killing of
paclitaxel-resistant cancer cells. Pharm Res. 31:1938–1945. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Acharya S and Sahoo SK: PLGA nanoparticles
containing various anticancer agents and tumour delivery by EPR
effect. Adv Drug Deliv Rev. 63:170–183. 2011. View Article : Google Scholar
|
|
125
|
Chapman VP, Stylianopoulos T, Martin JD,
Popović Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D and Jain RK:
Normalization of tumour blood vessels improves the delivery of
nanomedicines in a size-dependent manner. Nat Nanotechnol.
7:383–388. 2012. View Article : Google Scholar
|
|
126
|
Jain RK and Stylianopoulos T: Delivering
nanomedicine to solid tumors. Nat Rev Clin Oncol. 7:653–664. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Olivares-Morales A, Kamiyama Y, Darwich
AS, Aarons L and Rostami-Hodjegan A: Analysis of the impact of
controlled release formulations on oral drug absorption, gut wall
metabolism and relative bioavailability of CYP3A substrates using a
physiologically-based pharmacokinetic model. Eur J Pharm Sci.
67:32–44. 2015. View Article : Google Scholar
|
|
128
|
Kyrodimou M, Andreadis D, Drougou A,
Amanatiadou EP, Angelis L, Barbatis C, Epivatianos A and
Vizirianakis IS: Desmoglein-3/γ-catenin and E-cadherin/β-catenin
differential expression in oral leukoplakia and squamous cell
carcinoma. Clin Oral Investig. 18:199–210. 2014. View Article : Google Scholar
|
|
129
|
Hrkach J, Von Hoff D, Mukkaram Ali M,
Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M,
Horhota A, et al: Preclinical development and clinical translation
of a PSMA-targeted docetaxel nanoparticle with a differentiated
pharmacological profile. Sci Transl Med. 4:128ra392012. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Hudachek SF and Gustafson DL:
Physiologically based pharmacokinetic model of lapatinib developed
in mice and scaled to humans. J pharmacokinet pharmacodyn.
40:157–176. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Poulin P, Hop CE, Salphati L and Liederer
BM: Correlation of tissue-plasma partition coefficients between
normal tissues and subcutaneous xenografts of human tumor cell
lines in mouse as a prediction tool of drug penetration in tumors.
J Pharm Sci. 102:1355–1369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Zhou Q, Guo P, Kruh GD, Vicini P, Wang X
and Gallo JM: Predicting human tumor drug concentrations from a
preclinical pharmacokinetic model of temozolomide brain
disposition. Clin Cancer Res. 13:4271–4279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Castorina P, Carcò D, Guiot C and
Deisboeck TS: Tumor growth instability and its implications for
chemotherapy. Cancer Res. 69:8507–8515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Ganguly R and Puri IK: Mathematical model
for chemotherapeutic drug efficacy in arresting tumour growth based
on the cancer stem cell hypothesis. Cell Prolif. 40:338–354. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Hubbard ME and Byrne HM: Multiphase
modelling of vascular tumour growth in two spatial dimensions. J
Theor Biol. 316:70–89. 2013. View Article : Google Scholar
|
|
136
|
Johnson D, McKeever S, Stamatakos G,
Dionysiou D, Graf N, Sakkalis V, Marias K, Wang Z, Deisboeck TS,
Johnson D, et al: Dealing with diversity in computational cancer
modeling. Cancer Inform. 12:115–124. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Loessner D, Flegg JA, Byrne HM, Clements
JA and Hutmacher DW: Growth of confined cancer spheroids: A
combined experimental and mathematical modelling approach. Integr
Biol. 5:597–605. 2013. View Article : Google Scholar
|
|
138
|
Molina-Peña R and Álvarez MM: A simple
mathematical model based on the cancer stem cell hypothesis
suggests kinetic commonalities in solid tumor growth. PLoS One.
7:e262332012. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Sakkalis V, Sfakianakis S, Tzamali E,
Marias K, Stamatakos G, Misichroni F, Ouzounoglou E, Kolokotroni E,
Dionysiou D, Johnson D, et al: Web-based workflow planning platform
supporting the design and execution of complex multiscale cancer
models. IEEE J Biomed Health Inform. 18:824–831. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Sturrock M, Hao W, schwartzbaum J and
rempala GA: A mathematical model of pre-diagnostic glioma growth. J
Theor Biol. 380:299–308. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Tzamali E, Grekas G, Marias K and Sakkalis
V: Exploring the competition between proliferative and invasive
cancer phenotypes in a continuous spatial model. PLoS One.
9:e1031912014. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
He Q, Guo S, Qian Z and Chen X:
Development of individualized anti-metastasis strategies by
engineering nanomedicines. Chem Soc Rev. 44:6258–6286. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Hu C, Niestroj M, Yuan D, Chang S and Chen
J: Treating cancer stem cells and cancer metastasis using
glucose-coated gold nanoparticles. Int J nanomedicine.
10:2065–2077. 2015.PubMed/NCBI
|
|
144
|
Landesman-Milo D, Ramishetti S and Peer D:
Nanomedicine as an emerging platform for metastatic lung cancer
therapy. Cancer Metastasis Rev. 34:291–301. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Patil R, Ljubimov AV, Gangalum PR, Ding H,
Portilla-Arias J, Wagner S, Inoue S, Konda B, Rekechenetskiy A,
Chesnokova A, et al: MRI virtual biopsy and treatment of brain
metastatic tumors with targeted nanobioconjugates: Nanoclinic in
the brain. ACS Nano. 9:5594–5608. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Rychahou P, Shu Y, Haque F, Hu J, Guo P
and Evers BM: Methods and assays for specific targeting and
delivery of RNA nanoparticles to cancer metastases. Methods Mol
Biol. 1297:121–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Swami A, Reagan MR, Basto P, Mishima Y,
Kamaly N, Glavey S, Zhang S, Moschetta M, Seevaratnam D, Zhang Y,
et al: Engineered nanomedicine for myeloma and bone
microenvironment targeting. Proc Natl Acad Sci USA.
111:10287–10292. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Sjögren E, Westergren J, Grant I, Hanisch
G, Lindfors L, Lennernäs H, Abrahamsson B and Tannergren C: In
silico predictions of gastrointestinal drug absorption in
pharmaceutical product development: Application of the mechanistic
absorption model GI-Sim. Eur J Pharm Sci. 49:679–698. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Jayachandran D, Ramkrishna U, Skiles J,
Renbarger J and Ramkrishna D: Revitalizing personalized medicine:
Respecting biomolecular complexities beyond gene expression. CPT
Pharmacometrics Syst Pharmacol. 3:e1102014. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Xie L, Ge X, Tan H, Xie L, Zhang Y, Hart
T, Yang X and Bourne PE: Towards structural systems pharmacology to
study complex diseases and personalized medicine. PLOS Comput Biol.
10:e10035542014. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Gröning R, Remmerbach S and Jansen AC:
Telemedicine: Insulin pump controlled via the Global System for
Mobile Communications (GSM). Int J Pharm. 339:61–65. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Alomari M, Mohamed FH, Basit AW and
Gaisford S: Personalised dosing: Printing a dose of one's own
medicine. Int J pharm. 494:568–577. 2015. View Article : Google Scholar
|
|
153
|
Khaled SA, Burley JC, Alexander MR and
Roberts CJ: Desktop 3D printing of controlled release
pharmaceutical bilayer tablets. Int J Pharm. 461:105–111. 2014.
View Article : Google Scholar
|
|
154
|
Xitian P, Hongying L, Kang W, Yulin L,
Xiaolin Z and Zhiyu W: A novel remote controlled capsule for
site-specific drug delivery in human GI tract. Int J Pharm.
382:160–164. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Farandos NM, Yetisen AK, Monteiro MJ, Lowe
CR and Yun SH: Contact lens sensors in ocular diagnostics. Adv
Healthc Mater. 4:792–810. 2015. View Article : Google Scholar
|
|
156
|
Wening K and Breitkreutz J: Oral drug
delivery in personalized medicine: Unmet needs and novel
approaches. Int J pharm. 404:1–9. 2011. View Article : Google Scholar
|
|
157
|
Vizirianakis IS: Harnessing
pharmacological knowledge for personalized medicine and
pharmacotyping: Challenges and lessons learned. World J Pharmacol.
3:110–119. 2014. View Article : Google Scholar
|
|
158
|
Li M, Panagi Z, Avgoustakis K and Reineke
J: Physiologically based pharmacokinetic modeling of PLGA
nanoparticles with varied mPEG content. Int J nanomedicine.
7:1345–1356. 2012.PubMed/NCBI
|
|
159
|
Shelley ML, Wagner AJ, Hussain SM and
Bleckmann C: Modeling the in vivo case with in vitro nanotoxicity
data. Int J Toxicol. 27:359–367. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Lin P, Chen JW, Chang LW, Wu JP, Redding
L, Chang H, Yeh TK, Yang CS, Tsai MH, Wang HJ, et al: Computational
and ultrastructural toxicology of a nanoparticle, Quantum Dot 705,
in mice. Environ Sci Technol. 42:6264–6270. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Péry AR, Brochot C, Hoet PH, Nemmar A and
Bois FY: Development of a physiologically based kinetic model for
99m-technetium-labelled carbon nanoparticles inhaled by humans.
Inhal Toxicol. 21:1099–1107. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Lankveld DP, Oomen AG, Krystek P, Neigh A,
Troost-de Jong A, Noorlander CW, Van Eijkeren JC, Geertsma RE and
De Jong WH: The kinetics of the tissue distribution of silver
nanoparticles of different sizes. Biomaterials. 31:8350–8361. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Mager DE, Mody V, Xu C, Forrest A, Lesniak
WG, Nigavekar SS, Kariapper MT, Minc L, Khan MK and Balogh LP:
Physiologically based pharmacokinetic model for composite
nanodevices: Effect of charge and size on in vivo disposition.
Pharm Res. 29:2534–2542. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Pascal J, Ashley CE, Wang Z, Brocato TA,
Butner JD, Carnes EC, Koay EJ, Brinker CJ and Cristini V:
Mechanistic modeling identifes drug-uptake history as predictor of
tumor drug resistance and nano-carrier-mediated response. ACS Nano.
7:11174–11182. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Li D, Johanson G, Emond C, Carlander U,
Philbert M and Jolliet O: Physiologically based pharmacokinetic
modeling of polyethylene glycol-coated polyacrylamide nanoparticles
in rats. nanotoxicology. 8(suppl 1): S128–S137. 2014. View Article : Google Scholar
|
|
166
|
Sweeney LM, MacCalman L, Haber LT, Kuempel
ED and Tran CL: Bayesian evaluation of a physiologically-based
pharmacokinetic (PBPK) model of long-term kinetics of metal
nanoparticles in rats. Regul Toxicol Pharmacol. 73:151–163. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Bachler G, Losert S, Umehara Y, von Goetz
N, Rodriguez-Lorenzo L, Petri-Fink A, Rothen-Rutishauser B and
Hungerbuehler K: Translocation of gold nanoparticles across the
lung epithelial tissue barrier: Combining in vitro and in silico
methods to substitute in vivo experiments. Part Fibre Toxicol.
12:182015. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Lin Z, Monteiro-Riviere NA and Riviere JE:
A physiolo gically based pharmacokinetic model for polyethylene
glycol-coated gold nanoparticles of different sizes in adult mice.
Nanotoxicology. 11:1–11. 2015. View Article : Google Scholar
|
